Table 3b. DFS and OS for patients centrally re-tested and HER2-positive.

			5-year rate
	Hazard ratio (95% CI)a	P-valueb	Abbreviated trastuzumab N=63	Conventional trastuzumab N=57
DFS	0.85 (0.41–1.77)	0.66	74%	78%
OS	1.21 (0.46–3.13)	0.70	94%	89%

Abbreviations: CI=confidence interval; DFS=disease-free survival; HER2=human epidermal growth factor receptor type 2; OS=overall survival.

^aHazard ratio for conventional trastuzumab vs abbreviated trastuzumab.

^bBased on log-rank test.